SAMSUNG-ELECTRONICS
18.11.2021 11:26:06 CET | Business Wire | Press release
Samsung Electronics, a world leader in advanced semiconductor technology, held its 3rd Annual Samsung Advanced Foundry Ecosystem (SAFETM ) Forum 2021 virtually today.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211118005659/en/
With the theme of 'Performance Platform 2.0: Innovation, Intelligence, Integration', Samsung and its foundry ecosystem partners prepared 7 plenary talks and 76 technology sessions focused on three main topics: Gate-All-Around (GAA, Innovation), Artificial Intelligence (AI, Intelligence), and 2.5D/3D (Integration) technologies and the diverse design infrastructures required for high-performance applications.
“In the rapidly changing data-centric era, Samsung and its foundry partners have made great strides responding to increasing customers demand and to support their success by providing powerful solutions,” said Ryan Lee, Senior Vice President and Head of Foundry Design Platform Development at Samsung Electronics. “With the support of our SAFE program, Samsung will lead the realization of the vision 'Performance Platform 2.0'.”
Starting with a keynote live streaming on November 17, attendees are able to explore a variety of tech sessions and engage with ecosystem partners through the virtual SAFE Forum platform for a month. To register for SAFE forum, please visit https://www.samsungfoundry.com
SAFE 2021: Performance Platform 2.0
Samsung has concentrated on expanding its foundry ecosystem by focusing on IP, Electronic Design Automation (EDA), Cloud, Design Solution Partner (DSP), and Package solutions necessary for today’s data-driven era. Samsung introduced today its latest SAFETM program including:
- SAFE™-IP & EDA: Samsung and its foundry ecosystem have reserved over 3,600 IPs and 80 certified EDA tools respectively. These are developed and verified based on the high-standard of certification program run by Samsung and participated in by our partners. In order to respond to the demands of high performance applications, Samsung’s foundry ecosystem has developed not only HPC-specific foundation IPs including standard cell libraries and memory compilers but also key IPs, such as over 100Gbps Serializer-Deserializer (SerDes) interface and 2.5D/3D multi-die integration solutions.
With our EDA partners, Samsung has secured design tools optimized for its unique 3-nanometer (nm) GAA process technology and design methodology for integrating multiple dies in 2.5D/3D. Customers can also utilize AI- and machine learning- based EDA technology to systematically manage and analyze design data. To overcome the increasing difficulties of chip design and analysis, Samsung has strengthened cooperation with partners to develop EDA tools and related technologies, such as incorporating GPUs that can efficiently use computing resources required for chip verification.
- SAFE™-OSAT: Samsung plans to lead ‘beyond-Moore’ technologies by strengthening various package line-ups such as 2.5D/3D through the expansion of its SAFE-Outsourced Semiconductor Assembly and Test (OSAT) ecosystem. The recent announcement of the co-development of Hybrid-Substrate Cube (H-Cube) solution, which offers efficient integration of 6 HBMs and cost benefit, is one of the successful examples of Samsung foundry’s collaboration with the OSAT community.
-
SAFE™-Cloud Design Platform
: SAFE™-CDP, the cloud-based one-stop design platform introduced last year, now supports a hybrid cloud function that can be linked to customers' conventional design environments.
- SAFE™-DSP : Through the SAFE™-DSP ecosystem, Samsung and its global partners can actively support global fabless companies to implement their design ideas into custom product by utilizing cutting-edge process technologies as well as high-performance, low-power chip design knowledge.
# # #
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at news.samsung.com
Quote from SAFETM Partner companies
- Ansys, Ajei Gopal, CEO
“Today’s chips demand a full multiphysics approach, which requires engineering simulation. Ansys is proud to partner with Samsung to deliver a comprehensive multi-physics analysis flow for Samsung’s multi-die integration initiative. The benefits to joint customers, to the industry – and to the entire world – are tremendous. Semiconductors will drive innovations as varied as autonomous and electric vehicles, artificial intelligence, and mobile technologies, including 5G and beyond.”
- Arm, Simon Segars, CEO
“Our longstanding partnership with Samsung Foundry has been essential for growing business opportunities in many markets for our combined partner ecosystem. This close collaboration continues as we work together to optimize our Armv9 next-generation processors on Samsung Foundry’s leading-edge processes, including GAA, to deliver a best-in-class solution that is optimized for the world of today, and the technologies of tomorrow. Together, we are unlocking new opportunities across HPC, Automotive, AI, and IoT, while also managing rising complexities, enabling faster time to market.”
- Cadence, Lip-Bu Tan, CEO
“The Cadence Intelligent System Design strategy is very well-aligned with Samsung Foundry’s Performance Platform 2.0 with common themes of innovation, pervasive intelligence and integrated solutions. Together, we’re enabling customers to develop and deliver innovative, breakthrough products using Samsung’s most advanced process and packaging technologies, and we look forward to continuing our work with Samsung Foundry to accelerate design successes.”
- Siemens EDA, A.J. Incorvaia, Senior Vice President
“Quo The Samsung SAFE event provides an exceptionally valuable venue for the Samsung Foundry ecosystem to meet, share information and identify opportunities to fully leverage Samsung’s cutting-edge process technologies. Siemens EDA looks forward to this year’s Samsung SAFE event and the many opportunities it presents for collaborating with customers and partners to eliminate design obstacles and enhance silicon success.”
- Synopsys, Sassine Ghazi, president and COO
“We see exciting times ahead as software and chip technology come together to create world-changing new products,” said Sassine Ghazi, president and COO of Synopsys. “We have strong programs with Samsung Foundry on 3nm gate-all-around enablement, broad IP certification, AI-assisted chip design and 2.5/3D multi-die design to name just a few. We welcome the strong collaboration opportunities offered by the Samsung SAFE initiative.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20211118005659/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Danish C-UAS Startup Shotling Raises €700K Oversubscribed Pre-Seed (Myriad-IPO CLUB-EIFO) for Anti-Drone Shotgun2.2.2026 07:35:00 CET | Press release
Shotling, a Danish defense technology startup specializing in kinetic short-range counter-UAS (C-UAS) systems, today announced the closing of a pre-seed financing round with €700K committed out of a targeted €500K. The round is led by Myriad Defense Fund, with co-investment from IPO CLUB’s Fund II America 2030, and a non-dilutive match-loan granted by EIFO, the Export and Investment Fund of Denmark, supporting Shotling’s mission to deliver rapid-fire modular shotgun systems against FPV drones and loitering munitions—as the global counter-UAS market accelerates towards $10B by 2030, with kinetic defense segment showing strong momentum (25%+ CAGR). Shotling’s rotary shotgun system provides unmatched close-range defense (50–100m) against the rapidly growing threat of kamikaze drones, combining a gatling-style design, with novel, high-capacity magazines, and firing rates up to 3,000 RPM using standard or tungsten-based 12-gauge shells. With deep expertise in weapons engineering and active
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults RelabotulinumtoxinA is designed to optimize molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for frown lines and crow’s feet and has been approved in over 20 markets, including in the European Union1-3 Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation
High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 08:00:00 CET | Press release
Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom